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ABSTRACT
Hereditary retinal diseases are now the leading cause of
blindness certiﬁcation in the working age population
(age 16–64 years) in England and Wales, of which
retinitis pigmentosa (RP) is the most common disorder.
RP may be complicated by cystoid macular oedema
(CMO), causing a reduction of central vision. The
underlying pathogenesis of RP-associated CMO (RP-
CMO) remains uncertain, however, several mechanisms
have been proposed, including: (1) breakdown of the
blood-retinal barrier, (2) failure (or dysfunction) of the
pumping mechanism in the retinal pigment epithelial, (3)
Müller cell oedema and dysfunction, (4) antiretinal
antibodies and (5) vitreous traction. There are limited
data on efﬁcacy of treatments for RP-CMO. Treatments
attempted to date include oral and topical carbonic
anhydrase inhibitors, oral, topical, intravitreal and
periocular steroids, topical non-steroidal anti-
inﬂammatory medications, photocoagulation, vitrectomy
with internal limiting membrane peel, oral lutein and
intravitreal antivascular endothelial growth factor
injections. This review summarises the evidence
supporting these treatment modalities. Successful
management of RP-CMO should aim to improve both
quality and quantity of vision in the short term and may
also slow central vision loss over time.
INTRODUCTION
Cystoid macular oedema (CMO) may complicate
retinitis pigmentosa (RP) and has been reported to
occur in 10%–50% of patients.1–4
Hereditary retinal diseases are now the leading
cause of blindness certiﬁcation in the working age
population (age 16–64 years) in England and
Wales, of which RP is the most common disorder.5
RP causes nyctalopia and progressive peripheral
visual ﬁeld loss, with particular disability experi-
enced when disease progression results in central
visual compromise. One important treatable cause
of central vision loss is RP-associated CMO
(RP-CMO).6 Improved understanding of the under-
lying mechanisms and response to treatments of
RP-CMO is required to facilitate better-targeted
and more efﬁcacious therapies. In this review, we
will discuss the pathogenesis of RP-CMO and the
multiple avenues of intervention that have been
investigated or being considered.
PATHOGENESIS
No single aetiology has been deﬁnitively established
to cause RP-CMO. While we describe several indi-
vidually proposed mechanisms, it is plausible that
RP-CMO may result from a combination of these.
Breakdown of the blood-retinal barrier
The blood-retinal barrier (BRB) exists to maintain
homeostasis via the highly selective diffusion and
active transport of molecules into and out of the
retina, thus preventing extravascular accumulation
of ﬂuid within the retina.7 This is achieved in two
ways: (i) an outer barrier of apical tight junctions
between retinal pigment epithelial (RPE) cells8 9
and (ii) an inner barrier of tight junctions between
vascular endothelial cells.10 CMO can occur from
BRB breakdown secondary to RPE and/or endothe-
lial damage/dysfunction.
Studies have investigated whether one barrier is
more affected than the other in order to better
focus on potential therapies. Vinores et al11 used
immunolocalisation of endogenous albumin to
highlight areas of extravasation in normal eyes
compared with those with RP. In eyes with RP
alone, albumin leakage was greatest from the inner
barrier.11 In RP-associated with other ocular com-
plications (eg, aphakia, glaucoma), leakage varied
between the inner and outer barriers. No correl-
ation was found between severity of photoreceptor
degeneration and albumin leakage,11 suggesting
that therapies for RP-CMO could be used regard-
less of underlying disease status.
The release of ‘toxic products’ from degenerating
retina/RPE may cause RP-CMO by disrupting the
BRB.12 In keeping with CMO observed in other
disorders, RP-CMO has been associated with
release of vascular endothelial growth factor
(VEGF), adenosine,7 prostaglandins,13 histamine,14
insulin-like growth factor 1,15 tumour necrosis
factor α and interleukin-1α and interleukin-1β.16
Failure (or dysfunction) of the pumping
mechanism in the RPE
An important function of the RPE is to pump ﬂuid
out from the subretinal space in order to maintain
the negative hydrostatic pressure required for adhe-
sion between RPE and photoreceptors.17 Under
normal conditions, Cl− enters the RPE cell via Na+/
K+ ATPase located on the apical membrane and
exits via Cl− channels on the basolateral membrane.
It is this active transport that drives water through
aquaporin channels from the subretinal space into
the choriocapillaris. Failure (or dysfunction) of this
pumping mechanism may occur in RP, thus resulting
in CMO. The presence of CMO has been suggested
to result in loss of polarised distribution of
membrane-bound carbonic anhydrase (CA) IV in the
RPE, further contributing to RP-CMO.10
Müller cell oedema and dysfunction
The Müller cell is essential for visual transduction
and retinal homeostasis, including ﬂuid dynamics.
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Water enters the retina by two routes: directly from the blood,
coupled with glucose uptake and/or as a by-product of aerobic
metabolism; with the bidirectional movement of water osmotic-
ally coupled with the transport of osmolytes such as
potassium.18
Potassium ions are released by activated retinal neurons. To
prevent a build-up and potential excitotoxicity, potassium is pas-
sively taken up into Müller cells via inwardly rectifying channels
(Kir2.1) with release of potassium occurring via Kir4.1 chan-
nels.18 Kir channels consist of two transmembrane regions with
cytosolic NH2 and COOH termini connected by a pore-forming
loop. Molecules such as Mg2+ and polyamines are able to phys-
ically block this channel pore from allowing outward movement
of K+, while still able to accept inward movement of K+19
Under pathological conditions such as inﬂammation and oxida-
tive stress, Kir4.1 channels redistribute, becoming more evenly
spread throughout the Müller cell. However, Kir2.1 channels
do not redistribute, resulting in intracellular potassium overload,
increased osmotic pressure within the Müller cell, reduction in
water efﬂux and ultimate Müller cell swelling.18
Makiyama et al used optical coherence tomography (OCT) to
investigate the prevalence and spatial distribution of cystoid
spaces (CS) in patients with RP. Seventy-four of 275 patients
(27%) demonstrated RP-CMO in at least one eye. Inner nuclear
layer (INL) CS were observed in 99% of eyes with CMO. The
outer nuclear layer (ONL)/outer plexiform layer was involved in
28% and ganglion cell layer involved in 7%.20 Müller cell
bodies reside in the INL, which supports the hypothesis of
Müller cell swelling and dysfunction. Interestingly, 79% of CS
were located in areas of relatively well-preserved outer retina;20
in keeping with the observation that CMO is seen more com-
monly in less advanced RP compared with late-stage RP.
Antiretinal antibodies
Serum levels of IgG, IgA and IgM have been investigated in 52
patients with RP compared with 40 controls. Higher levels of
IgM were found in patients with RP compared with controls.21
Spiro et al,22 however, found no difference in IgM levels
between 75 patients with RP and 51 controls. Spalton et al per-
formed immunological studies on 17 patients with RP with
central and/or peripheral vascular leakage observed on ﬂuores-
cein angiogram (FA). Five out of 17 patients had raised IgM
unrelated to degree of vascular leakage. All patients demon-
strated positive immunoﬂuorescence to rat photoreceptors at
1:5 dilution of serum, however, this could be attributed to
cross-reactivity of smooth muscle antibodies with photoreceptor
contractile organelles.12
Antiretinal antibodies have been prospectively studied in 30
patients with RP-CMO and 30 patients with RP without CMO.
Antiretinal antibodies were found in 27 of 30 patients with
RP-CMO compared with 4 of 30 patients with RP without
CMO.23 Nevertheless, the role of antiretinal antibodies in RP
progression or RP-CMO remains unclear, with many
unanswered questions including whether they are a secondary
consequence of the degenerative process, the wide range of
autoantibodies identiﬁed and the high prevalence in normal
controls.23 24
Vitreous traction
It has been suggested that vitreous traction and epiretinal mem-
brane contributes to RP-CMO by causing mechanical damage to
Müller cells, an inﬂammatory reaction with subsequent capillary
dilatation and leakage.25 26 Schepens et al26 and Takezawa
et al27 have reported cases of RP-CMO in the presence of vitre-
ous traction.
DIAGNOSIS AND MONITORING OF RP-CMO
Prior to the advent of OCT, monitoring RP-CMO included
slit-lamp biomicroscopy together with FA. OCT has since been
shown to be more sensitive in detecting macular oedema com-
pared with biomicroscopy in patients with diabetic retinopathy
and RP-CMO.28 29 OCT can detect CS in RP-CMO even when
little, or no leakage is demonstrated on FA29 30 and being non-
invasive is ideal for monitoring RP-CMO. No studies have yet
been performed using OCT-Angiography to investigate
RP-CMO.
RP-CMO is not always associated with a reduction in visual
acuity (VA).31 Oishi et al32 found no correlation between total
macular thickness and VA. The integrity of the inner segment
ellipsoid layer, however, has been shown to correlate well with
VA and inform the likely prognosis.31–33 Central vision loss in
RP-CMO may be due to retinal thinning (from atrophy), thick-
ening (from CMO) or a combination of both.34 Anatomical but
not functional improvement following treatment could be due
to underlying retinal dysfunction/loss.
Automated static perimetry may also be useful for monitoring
RP-CMO given the documented correlation between changes in
retinal thickness due to CMO and retinal sensitivity.35–37
INHERITANCE PATTERNS AND SPECIFIC ASSOCIATIONS
While pedigree structures may be informative, deﬁnitive conclu-
sions on mode of inheritance can only be made with a molecu-
lar diagnosis.
In a retrospective cohort study, CMO was present in 133/581
(23%) Italian patients with RP. This appeared to be signiﬁcantly
associated with autosomal dominant (AD) inheritance.2 In con-
trast, Liew et al38 constructed pedigrees for patients with
RP-CMO in a retrospective cohort and found 55/81 (68%)
patients with autosomal recessive (AR) inheritance (4 of whom
were molecularly proven).
A family with AD-RP associated with the p.P347L variant in
rhodopsin (RHO) has been reported, where all four children
had bilateral CMO, suggesting this RHO mutation may be asso-
ciated with early onset CMO.39
RP-CMO has been associated with female gender2 and does
not appear to be age-related.1
AVENUES OF INTERVENTION
Despite RP being the most common inherited retinal degener-
ation in the working age population, it remains a rare condition
with only a proportion of these patients developing CMO.5
Therefore, it is challenging to set up clinical trials targeting
RP-CMO, with most evidence to date comprising case reports/
series and relatively small prospective/retrospective studies.
We conducted a PubMed search to include all reports/studies of
interventional treatment for RP-CMO published between 1975
and 2016. The search strategy involved the terms ‘RP’, ‘rod cone
dystrophy’, ‘retinal dystrophy’, ‘inherited retinal dystrophy’ and
‘macular oedema’. We identiﬁed 203 publications, the abstracts of
which were retrieved and reviewed. Inclusion criteria included
prospective and retrospective reports/studies using a drug and/or
procedure to treat RP-CMO. We also included patients with syn-
dromic RP such as Usher syndrome and those with Coats-like
exudation. We excluded patients with membrane-type frizzled-
related protein (MFRP)-related nanophthalmos-retinitis pigment-
osa-foveoschisis-optic disc drusen syndrome due to its complexity
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and rarity. We identiﬁed 46 reports/studies that met our inclusion
criteria and retrieved these articles.
The majority of published evidence was in the form of small
cohort and case-control studies. These may be inﬂuenced by
publication bias, as negative reports are less likely to be pub-
lished. There are no large randomised control trials (RCTs) to
date. We did not construct funnel plots or perform other statis-
tical tests for publication bias due to the small number of studies
and the highly heterogeneous populations and study designs.
Signiﬁcant studies that describe interventions in detail or
highlight important/interesting points are mentioned in the text.
Online supplementary table S1 provides an overview of all
studies that met our inclusion criteria.
Pharmacological
CA inhibitors: oral and topical
Inhibition of CA IV results in acidiﬁcation of the subretinal
space, increased chloride ion transport, with subsequent move-
ment of water across the RPE into the choroid.10
Several studies have shown RP-CMO improvement following
treatment with CA inhibitors (CAIs).38 40–53 In the largest retro-
spective study to date involving 81 patients (157 eyes) with
RP-CMO, objective improvement on OCTwas observed in 53%
of patients (40% of eyes) using topical dorzolamide and in 41%
of patients (28% of eyes) using oral acetazolamide38 (ﬁgure 1).
VA improved from 6/15 to 6/12 in most patients. AR-RP and
greater initial central macular thickness (CMT) predicted better
response to treatment.
In another retrospective study, 33 eyes (51%) of 20 patients
with RP-CMO using topical dorzolamide demonstrated CMT
reduction of at least 11%.46 While there are other reports in
keeping with these ﬁndings,42 some studies have documented
improvement of anatomy or leakage on FA only, with little or
no corresponding improvement in VA.47–49
In a prospective, crossover study, 9 out of 17 patients using
oral methazolamide demonstrated angiographic improvement of
CMO, however, VA improved in at least one eye, by at least 2
lines in only 3 patients.43 Another prospective, masked, cross-
over study using oral acetazolamide versus placebo observed VA
improvement of at least one line, in at least one eye in 10 out of
12 patients. Three of these patients initiated on placebo only
demonstrated improvement once switched to acetazolamide.44
Location of CS in RP-CMO may inﬂuence response to treat-
ment with CAIs. Acetazolamide cannot readily enter the neuro-
sensory retina making it potentially less effective at reducing
INL CS.54 However, with good access to the RPE basolateral
membrane,41 acetazolamide may be more effective at reducing
ONL CS.55
Rebound CMO has been observed after stopping CAIs.42 47
Importantly, a restored response has been demonstrated after
the re-introduction of CAI treatment following a period of dis-
continued usage (between 1 and 6 months) in three patients
with rebound RP-CMO.53
Oral CAIs have more side effects than topical CAIs ranging
from fatigue, loss of appetite and limb paraesthesia to the devel-
opment of kidney stones, aplastic anaemia and electrolyte dis-
turbance including hypokalaemia with potential associated
cardiac arrhythmia.55
Steroids: oral, periocular and intravitreal
Steroids reduce the synthesis and release of pro-inﬂammatory
cytokines, including: prostaglandins, leukotrienes, VEGF and
Figure 1 Spectral domain optical coherence tomography of a man aged 30 years with autosomal recessive retinitis pigmentosa and cystoid
macular oedema. (A) Before treatment was initiated (visual acuity (VA) 6/18). (B) Following 6 months usage of topical carbonic anhydrase inhibitors
(VA 6/12).
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intercellular adhesion molecule 1.56–59 This, together with sup-
pression of inﬂammatory cell proliferation and migration contri-
butes to improved BRB function and reduction of CMO.
Steroids have been observed to improve VA and/or CMT in
RP-CMO.4 6 60–74
A 1-year pilot study using oral deﬂazacort in 10 patients with
RP-CMO reported signiﬁcant improvements in near VA, retinal
sensitivity and angiographic ﬁndings.64 No ocular or systemic
side effects were recorded.
Five patients with RP-CMO underwent unilateral intravitreal
injection of 4 mg (0.1 mL) of triamcinolone acetonide (IVTA).
CMT improved from 418 mm (range, 376–626 mm) at baseline
to 224 mm (range, 214–326 mm) at 1 month, 275 mm (range,
215–584 mm) at 3 months and 312 mm (range, 239–521 mm) at
6 months. VA improved in two patients by 1 month but was not
maintained. CMO recurrence occurred in two patients between
3 and 6 months.4
In comparison, a prospective, non-randomised trial compared
20 eyes of 20 patients with RP-CMO treated with IVTA with 20
eyes of 20 patients with RP-CMO who declined treatment. All
treated patients showed anatomical improvement, greatest at
3 months postinjection. No statistical improvement in VA was
observed. At day 1 post-IVTA, 10 eyes (50%) had a raised
intraocular pressure (IOP) (>21 mm Hg) including 2 patients
(10%) measuring between 30 and 35 mm Hg. All IOPs returned
to baseline within 6 months.6
A case report of bilateral RP-CMO refractory to IVTA
reported CMO reduction and VA improvement following bilat-
eral sub-Tenon injections of triamcinolone.62 CMO recurred in
one eye at 3 months.
Intravitreal dexamethasone implant (Ozurdex, Allergan,
Irvine, California, USA) has also been used in three patients
with RP-CMO refractory to oral CAIs and/or sub-Tenon triamci-
nolone and/or topical non-steroidal anti-inﬂammatory (NSAID).
Two patients required retreatment at 3 months due to recur-
rence.72 Another case report demonstrated similar outcomes
with initial improvement of CMO and VA, but recurrence at 2–
3 months.68
The use of regular steroids in RP-CMO is signiﬁcantly limited
by their side-effect proﬁle. Ozurdex appears to have a lower
incidence of cataract and raised IOP compared with IVTA in
treatment of retinal vein occlusion-CMO,75 76 however, the inci-
dence in RP-CMO is unknown.
Combination of topical NSAID together with topical steroid or
topical CAI
A case report using topical steroid (prednisolone acetate 1%)
together with topical NSAID (ketorolac trometamol 0.5%) in a
woman aged 85 years with unilateral RP-CMO demonstrated
CMO resolution and VA improvement at 3 months. CMO
recurrence on cessation required retreatment to good effect.77
A recent prospective study of 18 patients randomised 15 eyes
to topical ketorolac and 13 eyes to topical dorzolamide for
12 months. No signiﬁcant change in CMT was observed in
either group. VA improved in both groups at 6 months,
however, this improvement was lost in the dorzolamide group at
12 months.78
Intravitreal anti-VEGF
The VEGF family includes VEGF-A, VEGF-B, VEGF-C,
VEGF-D and placental growth factor.79 In addition to promot-
ing angiogenesis, VEGF-A reduces endothelial barrier function
and increases permeability of choroidal vessels, both of which
cause CMO.79
Salom et al identiﬁed markedly lower levels of VEGF-A in the
aqueous humour of 16 eyes of 16 patients with RP (94.9±99.8
(mean±SD) pg/mL) compared with the same number of con-
trols (336.5±116.8 pg/mL). Relative hyperoxia of the inner
retina due to photoreceptor cell death may reduce VEGF pro-
duction from retinal cells such as pericytes, endothelial cells,
glial cells, Müller cells and ganglion cells.80
While no studies have assessed vitreous levels of VEGF in
patients with RP or RP-CMO, anatomical and/or functional
improvement of RP-CMO has been observed following intravi-
treal anti-VEGF medication.81–86 Anti-VEGF agents are rou-
tinely used to treat CMO and neovascularisation (NV) in
multiple retinal diseases. NV is rare in RP; Triolo et al87
reported choroidal NV in 3 of 176 eyes (2%) with RP. Indeed,
intravitreal bevacizumab (Avastin, Genentech/Roche, South
San Francisco, California, USA) has been observed to improve
RP-choroidal NV.88 89 While VEGF may contribute to RP-CMO
formation, anti-VEGF medication remains under active study as
a treatment modality.
Pegaptanib
A case report using a single intravitreal injection of 0.3 mg
pegaptanib (Macugen, Eyetech Pharmaceuticals and Pﬁzer,
New York, New York, USA) together with oral acetazolamide in
a man aged 33 years with RP-CMO demonstrated improvement
of CMTand VA, which was maintained at 4 months.81
Bevacizumab
Bevacizumab has been used off-label to treat RP-CMO with
varying results. Melo et al observed neither anatomical nor
functional improvement in two eyes of two patients following
treatment with a single injection of intravitreal 1.25 mg bevaci-
zumab: case 1 maintained VA of 20/200 both prebevacizumab
and postbevacizumab injection with no further improvement
following IVTA. Case 2 had a baseline VA of 20/100, which
worsened at 1 month postbevacizumab to 20/200. Due to wor-
sening cataract, the patient subsequently underwent phacoemul-
siﬁcation plus IVTA and VA at 3 months postoperation
improved to 20/25.90 In contrast, Yuzbasioglu et al performed
an average of 3.3 (range, 1–8) injections of 1.25 mg bevacizu-
mab over 10.3 (range, 6–14) months in 13 eyes of 7 patients
and observed a reduction of CMT from 370.15 mm (range,
245–603 mm) at baseline to 142.53 mm (range, 124–168 mm).
Pretreatment and post-treatment VA ranged from 5/400–20/100
to 20/200–20/63, respectively.82
Ranibizumab
Artunay et al enrolled 30 eyes of 30 patients with RP-CMO into
a prospective, controlled interventional study of 0.5 mg intravi-
treal ranibizumab (Lucentis; Genentech). Thirteen eyes (87%) in
the treatment group demonstrated a signiﬁcant reduction of
CMO at 6 months. No statistically signiﬁcant difference in VA
was seen between the groups.83
Aﬂibercept
Improvement of CMTand VA following a single unilateral intra-
vitreal injection of aﬂibercept (Eylea; Regeneron
Pharmaceuticals, Tarrytown, New York, USA and Bayer
Healthcare Pharmaceuticals, Berlin, Germany) in a patient aged
52 years with RP-CMO was observed and maintained at 6
months.84 We have observed similar responses85 and have com-
menced a prospective study to determine safety and efﬁcacy of
intravitreal aﬂibercept in RP-CMO (ClinicalTrials.gov identiﬁer
NCT02661711). Aﬂibercept may be superior to other
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anti-VEGF medications due to its intermediate size (115 kDa)
and higher binding afﬁnity.
Nutritional
Oral lutein
Lutein and zeaxanthin are carotenoid pigments that contribute
to the formation of macular pigment, which is thought to be
protective against oxidative damage.91 A 48-week study tested
the effect of oral lutein on CMT in 39 patients with RP. Lutein
was found to have no statistically signiﬁcant effect on CMT in
patients with RP with or without CMO.3
Oral iodine
While oral iodine has not been trialled speciﬁcally for RP-CMO,
higher urinary iodine concentration has been observed to be sig-
niﬁcantly associated with reduced CMT in non-smoking adults
with RP-CMO.92
Surgical
Laser
In 1987, grid laser photocoagulation was undertaken in one eye
of 16 patients with bilateral RP-CMO. Six treated eyes gained
one or more lines of vision, while none of the untreated eyes
did. Seven untreated eyes lost one or more lines of vision, while
none of the treated eyes did. Thirteen of 16 eyes showed
decreased ﬂuorescein leakage after treatment.93 Laser may
remove hypoxic degenerating retina, thus reducing VEGF
production.94
Vitrectomy
In 2003, vitrectomy combined with inner limiting membrane
peel was carried out on 12 eyes of 8 patients with RP-CMO
refractory to treatment with acetazolamide. The presence or
absence of preoperative vitreomacular traction was not con-
ﬁrmed. Mean CMT improved from 478 mm (range, 380–
570 mm) preoperatively to 260 mm (range, 177–424 mm) at
6 months. Mean VA improved from 20/115 (range, 20/60–20/
400) preoperatively to 20/45 (range, 20/30–20/100) at 6
months.25
Conclusions and future directions
RP-CMO commonly complicates RP, however, its exact under-
lying pathogenesis remains uncertain. Proposed mechanisms
that are most likely to be involved include breakdown of the
BRB and/or RPE pump mechanism failure and/or Müller cell
oedema and dysfunction. When CS are present they are most
commonly located in the INL, suggesting that inner BRB dys-
function may have a greater role than the outer BRB, in devel-
opment of RP-CMO. A better understanding of these
mechanisms will facilitate better targeted and likely more efﬁca-
cious and durable therapies.
Setting up clinical trials for RP-CMO, however, remains a
challenge due to its low prevalence, the highly variable course
of disease progression, signiﬁcant genetic and allelic heterogen-
eity and very slow progression to visual loss. With the majority
of studies producing levels of evidence between 3 and 4 and no
large RCTs, we remain in a position where there are no studies
yet providing high-level evidence for RP-CMO treatments. In
the absence of RCTs, the effect of known and unknown con-
founders cannot be excluded. The majority of studies did not
have a control group (level 4 evidence) inherently limiting the
validity of ﬁndings, as these may be a result of natural history
rather than the intervention. Many studies were retrospective
which may be affected by recall bias. This review has
highlighted the lack of high-quality evidence for RP-CMO treat-
ments. While concrete conclusions cannot be drawn, the evi-
dence currently available suggests that topical CAIs may be used
as a ﬁrst-line approach. Consideration should be given to the
possibility of side effects and potential for rebound CMO. Oral
CAIs may be a second-line agent, but there is the risk of more
side effects.
As there are currently no treatments for the underlying retinal
degeneration in RP and given the potentially reversible nature of
RP-CMO, there is a real need to better understand disease
mechanisms and undertake prospective clinical trials of thera-
peutic agents to provide the evidence base to improve treatment
of RP-CMO. Successful management of CMO should aim to
both improve quality and quantity of vision in the short term
and slow the rate of vision loss over time.
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